Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy
A 65-year-old woman who was receiving lecanemab for early Alzheimer’s disease died from a massive brain hemorrhage that some researchers link to the drug.